Table 1 The relationship between TPM4 mRNA expression and clinical characteristics in glioma
Characteristic | Low expression of TPM4 | High expression of TPM4 | p |
|---|---|---|---|
n | 348 | 348 | |
WHO grade, n (%) | < 0.001 | ||
G2 | 180 (28.3%) | 44 (6.9%) | |
G3 | 120 (18.9%) | 123 (19.4%) | |
G4 | 2 (0.3%) | 166 (26.1%) | |
IDH status, n (%) | < 0.001 | ||
WT | 36 (5.2%) | 210 (30.6%) | |
Mut | 311 (45.3%) | 129 (18.8%) | |
1p/19q codeletion, n (%) | < 0.001 | ||
codel | 133 (19.3%) | 38 (5.5%) | |
noncodel | 215 (31.2%) | 303 (44%) | |
Primary therapy outcome, n (%) | < 0.001 | ||
PD | 53 (11.5%) | 59 (12.8%) | |
SD | 90 (19.5%) | 57 (12.3%) | |
PR | 49 (10.6%) | 15 (3.2%) | |
CR | 106 (22.9%) | 33 (7.1%) | |
Age, n (%) | < 0.001 | ||
<=60 | 311 (44.7%) | 242 (34.8%) | |
>60 | 37 (5.3%) | 106 (15.2%) | |
Histological type, n (%) | < 0.001 | ||
Astrocytoma | 112 (16.1%) | 83 (11.9%) | |
Glioblastoma | 2 (0.3%) | 166 (23.9%) | |
Oligoastrocytoma | 90 (12.9%) | 44 (6.3%) | |
Oligodendroglioma | 144 (20.7%) | 55 (7.9%) | |
Age, median (IQR) | 40 (32, 50.25) | 53 (38, 63) | < 0.001 |